Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for Maintaining Remission in Nephrotic Syndrome (NEMO)
NCT00981838Phase 3Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Apr 2009
- Primary completion
- Apr 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab in nephrotic syndrome, minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Recurrence of Nephrotic Syndrome at 12 months. Started Apr 2009; status: completed.
02
Drugs
rituximab
03
Conditions
nephrotic syndromeminimal change disease (MCD)focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT00981838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00981838.